Formulation: A solid
Formal Name: 1-(butyl-d9)-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Purity: ≥99% deuterated forms (d1-d9)
Formula Markup: C18H19D9N2O
Formula Weight: 297,5
Shelf life (days): 1460
CAS Number: 474668-57-0
Notes: Bupivacaine-d9 is intended for use as an internal standard for the quantification of bupivacaine (Item No. 16618) by GC- or LC-MS. Bupivacaine is a sodium channel blocker and local anesthetic.{49026,49029} It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.{49030,49027} Bupivacaine (10 µM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).{49026,49028} It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 (Item No. 10009019).{49029} Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals.
English
Deutsch
